Other News To Note
Tuesday, November 13, 2012
Morphotek Inc., of Exton, Pa., a subsidiary of Eisai Inc., said it has been granted FDA orphan drug designation for its investigational cancer drug, amatuximab (MORAb-009), a chimeric IgG1 antibody that targets a cell surface glycoprotein, mesothelin.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.